Michael Stephen, MD
Pulmonary Disease · Philadelphia, PANPI 1245393743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $205 of the $304 with a category attached, or 67.4%. 7 manufacturers reported payments, led by AstraZeneca at 39.2% of the total. Reporting peaked in 2021 at $218 and has fallen 91.0% since, to $20 in 2024. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 7 payments — averaging $43.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$119
- Insmed, Inc.$99
- Vivus LLC$22
- Optinose US, Inc.$20
- Philips North America LLC$18
- AbbVie$13
- plus $13 from 1 others
Across 11 payments — averaging $3799.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$40K
- AbbVie$1K
- Vivus LLC$326
What the payments were for
- Food & beverage$20567%
- Education$9933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $119 |
| Insmed, Inc. | 1 | $99 |
| Vivus LLC | 1 | $22 |
| Optinose US, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| AbbVie | 1 | $13 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$119
How this compares
$304 in reported general payments places this provider in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 189 | $167,124 |
| Dupixent PenDupilumab | 24 | $88,735 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $77,495 |
| Spiriva RespimatTiotropium Bromide | 107 | $66,534 |
| TezspireTezepelumab-Ekko | 11 | $48,459 |
| Incruse ElliptaUmeclidinium Bromide | 91 | $45,215 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $42,477 |
| Advair HfaFluticasone Propion/Salmeterol | 54 | $25,114 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,175 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 123 | $18,144 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $14,905 |
| Arnuity ElliptaFluticasone Furoate | 47 | $11,583 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,024 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 196 | $6,127 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $5,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $119 | $74,06861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.